AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28032249 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute neurological injury (ANI) patients
Number of subjects: 275
Study 28032249 — intervention group
Group type: EXPERIMENTAL
Intervention: Family caregivers of ANI patients
Number of subjects: 275
Study 28032249 — intervention group
Group type: COMPARATOR
Intervention: Cancer patients
Number of subjects: 275
Study 28032249 — intervention group
Group type: COMPARATOR
Intervention: Family caregivers of cancer patients
Number of subjects: 275
Study 26348718 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafluprost
Number of subjects: 41
Study 26348718 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost
Number of subjects: 41
Study 23500276 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure device
Number of subjects: 547
Study 23500276 — intervention group
Group type: COMPARATOR
Intervention: Warfarin therapy
Number of subjects: 547
Study 23500276 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial appendage closure device (warfarin naive subgroup)
Number of subjects: 547
Study 23500276 — intervention group
Group type: COMPARATOR
Intervention: Warfarin therapy (warfarin naive subgroup)
Number of subjects: 547
Study 22076546 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab monotherapy for 54 weeks
Number of subjects: 16
Study 19360548 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing (one stick of sugarless gum three times per day for one hour each day)
Number of subjects: 30
Study 19360548 — intervention group
Group type: COMPARATOR
Intervention: Standardized postoperative care (control group)
Number of subjects: 30
Study 16772027 — intervention group
Group type: EXPERIMENTAL
Intervention: PD on medication
Number of subjects: 669
Study 16772027 — intervention group
Group type: COMPARATOR
Intervention: PD off medication
Number of subjects: 669
Study 16772027 — intervention group
Group type: COMPARATOR
Intervention: PSP
Number of subjects: 669
Study 11808969 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (70 mg once weekly)
Number of subjects: 277
Study 11808969 — intervention group
Group type: COMPARATOR
Intervention: Placebo (once weekly)
Number of subjects: 277
Study 11808969 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (650 mg q.i.d. for last week)
Number of subjects: 277
Study 10078978 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomous mood disorder
Number of subjects: 67
Study 10078978 — intervention group
Group type: COMPARATOR
Intervention: Nonautonomous mood disorder
Number of subjects: 67
Study 10078978 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment completion
Number of subjects: 67
Study 7569760 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cromolyn sodium (1500 mg/day) for 1 month
Number of subjects: 428
Study 7569760 — intervention group
Group type: COMPARATOR
Intervention: Elimination diet
Number of subjects: 428
Study 2160495 — intervention group
Group type: EXPERIMENTAL
Intervention: A&D UA-751 semi-automated cuff-oscillometric sphygmomanometer
Number of subjects: 200
Study 2160495 — intervention group
Group type: COMPARATOR
Intervention: Hawksley random-zero mercury sphygmomanometer
Number of subjects: 200
Study 6996132 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 97
Study 6996132 — intervention group
Group type: COMPARATOR
Intervention: Pyridoxine
Number of subjects: 97
Study 29976188 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured yoga intervention consisting of five days of structured yoga training and practice at home for 90 days, along with two hours of health education on lifestyle modifications.
Number of subjects: 140
Study 29976188 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving two hours of health education on lifestyle modifications only.
Number of subjects: 140
Study 27206923 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenograft bone‐substitute material (Bio‐Oss Collagen®) placed in the fresh sockets along with immediate denture placement
Number of subjects: 34
Study 27206923 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment including denture placement immediately after extractions
Number of subjects: 34
Study 27206923 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenograft bone‐substitute material (Bio‐Oss Collagen®)
Number of subjects: 34
Study 27206923 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 34
Study 25626409 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 mmol vinegar (6% acetic acid)
Number of subjects: 8
Study 23107353 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin infusion site warming device (InsuPatch)
Number of subjects: 13
Study 23107353 — intervention group
Group type: COMPARATOR
Intervention: No InsuPatch activation (Control)
Number of subjects: 13
Study 21435365 — intervention group
Group type: EXPERIMENTAL
Intervention: Solid breakfast (oatmeal, blueberries, and apples)
Number of subjects: 14
Study 21435365 — intervention group
Group type: COMPARATOR
Intervention: Liquid breakfast (fruit juices and skim milk)
Number of subjects: 14
Study 21435365 — intervention group
Group type: EXPERIMENTAL
Intervention: Both meals (solid and liquid)
Number of subjects: 14
Study 18855229 — intervention group
Group type: EXPERIMENTAL
Intervention: Community skills training (local shops)
Number of subjects: 40
Study 18855229 — intervention group
Group type: COMPARATOR
Intervention: Classroom-based training
Number of subjects: 40
Study 18855229 — intervention group
Group type: COMPARATOR
Intervention: Community-based training
Number of subjects: 40
Study 18855229 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 40
Study 16785373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive educational intervention
Number of subjects: 202
Study 16785373 — intervention group
Group type: COMPARATOR
Intervention: Standard education
Number of subjects: 202
Study 12837861 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 12); daily extension and flexion range of motion against passive resistance (5 minutes per day, 5 days per week, for 4 weeks)
Number of subjects: 24
Study 12837861 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 12)
Number of subjects: 24
Study 10894281 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T‐3TC‐IDV
Number of subjects: 109
Study 10894281 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV‐3TC‐IDV
Number of subjects: 109
Study 10894281 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T‐ddI‐IDV
Number of subjects: 109
Study 10894281 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 109
Study 8794955 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled methanol at 200 ppm for 4 hours
Number of subjects: 22
Study 2004725 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 mg intravitreal dexamethasone phosphate
Number of subjects: 57
Study 2004725 — intervention group
Group type: COMPARATOR
Intervention: Control (no injection)
Number of subjects: 57
Study 6346848 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide, 50 mg
Number of subjects: 0
Study 6346848 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide, 2.5 mg
Number of subjects: 0
Study 29691794 — intervention group
Group type: EXPERIMENTAL
Intervention: ASAP intervention
Number of subjects: 161
Study 29691794 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual control
Number of subjects: 161
Study 26282583 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased sedentary time (SED-time)
Number of subjects: 326
Study 26282583 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased physical activity energy expenditure (PAEE)
Number of subjects: 326
Study 26282583 — intervention group
Group type: EXPERIMENTAL
Intervention: Kidney function measures (eGFR, serum creatinine, urine ACR)
Number of subjects: 326
Study 24636035 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person training
Number of subjects: 0
Study 24636035 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training
Number of subjects: 0
Study 24636035 — intervention group
Group type: COMPARATOR
Intervention: Mailed materials
Number of subjects: 0
Study 24636035 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 0
Study 23104075 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting (HV)
Number of subjects: 643
Study 23104075 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 643
Study 20737518 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-vitamin/mineral supplement (Supradyn)
Number of subjects: 216
Study 20737518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 18334081 — intervention group
Group type: EXPERIMENTAL
Intervention: NSAID use postoperatively
Number of subjects: 555
Study 16177617 — intervention group
Group type: EXPERIMENTAL
Intervention: One set fast (approximately 140 degrees.s(‐1))
Number of subjects: 115
Study 16177617 — intervention group
Group type: EXPERIMENTAL
Intervention: Three sets fast
Number of subjects: 115
Study 16177617 — intervention group
Group type: EXPERIMENTAL
Intervention: One set slow (approximately 50 degrees.s(‐1))
Number of subjects: 115
Study 16177617 — intervention group
Group type: EXPERIMENTAL
Intervention: Three sets slow
Number of subjects: 115
Study 16177617 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast training
Number of subjects: 115
Study 16177617 — intervention group
Group type: EXPERIMENTAL
Intervention: Three sets or fast speeds
Number of subjects: 115
Study 16177617 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 115
Study 12947070 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate 1,500 mg IV every 3 weeks + mitoxantrone 12 mg/m2 IV every 3 weeks + prednisone 5 mg orally bid
Number of subjects: 209
Study 12947070 — intervention group
Group type: COMPARATOR
Intervention: Placebo + mitoxantrone 12 mg/m2 IV every 3 weeks + prednisone 5 mg orally bid
Number of subjects: 209
Study 10493337 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional inactivated influenza A vaccine
Number of subjects: 547
Study 10493337 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study 8614525 — intervention group
Group type: EXPERIMENTAL
Intervention: 311C90 1 mg
Number of subjects: 84
Study 8614525 — intervention group
Group type: EXPERIMENTAL
Intervention: 311C90 5 mg
Number of subjects: 84
Study 8614525 — intervention group
Group type: EXPERIMENTAL
Intervention: 311C90 25 mg
Number of subjects: 84
Study 8614525 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 84
Study 1533289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous m-chlorophenylpiperazine (MCPP) 0.06 mg/kg
Number of subjects: 9
Study 1533289 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous m-chlorophenylpiperazine (MCPP) 0.08 mg/kg
Number of subjects: 9
Study 1533289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 3919556 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg of bepridil hydrochloride
Number of subjects: 178
Study 3919556 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of bepridil hydrochloride
Number of subjects: 178
Study 3919556 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg of bepridil hydrochloride
Number of subjects: 178
Study 3919556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 30720354 — intervention group
Group type: EXPERIMENTAL
Intervention: gshFBT
Number of subjects: 100
Study 29982509 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate/emtricitabine
Number of subjects: 805
Study 29982509 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir
Number of subjects: 805
Study 26827971 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable retainers containing silver nanoparticles (about 40 nm in size and 500 ppm in concentration)
Number of subjects: 66
Study 26827971 — intervention group
Group type: COMPARATOR
Intervention: Conventional removable retainers
Number of subjects: 66
Study 25052821 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled reoxygenation CPB
Number of subjects: 79
Study 25052821 — intervention group
Group type: COMPARATOR
Intervention: Standard oxygen levels CPB
Number of subjects: 79
Study 22743160 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational Enhancement Therapy/Cognitive Behavioral Therapy (MET/CBT)
Number of subjects: 112
Study 22743160 — intervention group
Group type: EXPERIMENTAL
Intervention: MET/CBT+Contingency Management (CM)
Number of subjects: 112
Study 22743160 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Counseling (DC)
Number of subjects: 112
Study 22743160 — intervention group
Group type: EXPERIMENTAL
Intervention: DC+CM
Number of subjects: 112
Study 22743160 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 112
Study 22743160 — intervention group
Group type: COMPARATOR
Intervention: All treatment types
Number of subjects: 112
Study 20693799 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sotalol (75 mg over 2.5 h)
Number of subjects: 15
Study 20693799 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sotalol (80 mg)
Number of subjects: 15
Study 20693799 — intervention group
Group type: EXPERIMENTAL
Intervention: QTc = 0.0342 (sotalol concentration) + 398
Number of subjects: 15
Study 18658112 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinovirus inoculation
Number of subjects: 0
Study 18658112 — intervention group
Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 0
Study 18658112 — intervention group
Group type: EXPERIMENTAL
Intervention: Viperin knockdown with short interfering RNA
Number of subjects: 0
Study 18658112 — intervention group
Group type: EXPERIMENTAL
Intervention: Naturally acquired rhinovirus infections
Number of subjects: 0
Study 18658112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured human epithelial cells infected with intact rhinovirus
Number of subjects: 0
Study 18658112 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured human epithelial cells infected with replication-deficient rhinovirus
Number of subjects: 0
Study 16151353 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (0.35 mg/kg daily for 18 weeks)
Number of subjects: 16
Study 16151353 — intervention group
Group type: COMPARATOR
Intervention: Diphenidol (25 mg/d) plus acetazolamide (250 mg/48 h)
Number of subjects: 16
Study 12486431 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 853
Study 10695780 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin 480 mg over 5 days
Number of subjects: 40
Study 10695780 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin 640 mg over 7 days
Number of subjects: 40
Study 7827868 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibody (MAb) and complement treatment
Number of subjects: 56
Study 7827868 — intervention group
Group type: EXPERIMENTAL
Intervention: Purged marrow grafts
Number of subjects: 56
Study 3163879 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg Zn/d
Number of subjects: 31
Study 3163879 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg Zn/d
Number of subjects: 31
Study 3163879 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 31860170 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk model based on identified risk factors (age, LDL, smoking, BMI, diabetes, OSAS, aspartate aminotransferase)
Number of subjects: 5561
Study 29622143 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorb BVS
Number of subjects: 150
Study 29622143 — intervention group
Group type: COMPARATOR
Intervention: CoCr-EES
Number of subjects: 150
Study 28096109 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of financial ties of principal investigators
Number of subjects: 195
Study 24553479 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior pericardial window technique (PW)
Number of subjects: 458
Study 24553479 — intervention group
Group type: COMPARATOR
Intervention: Control (traditional technique)
Number of subjects: 458
Study 23180503 — intervention group
Group type: EXPERIMENTAL
Intervention: Protocolized sedation plus daily sedation interruption (n = 214)
Number of subjects: 430
Study 23180503 — intervention group
Group type: COMPARATOR
Intervention: Protocolized sedation (control) (n = 209)
Number of subjects: 430
Study 20683334 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 2.0 mg kg(‐1)
Number of subjects: 98
Study 20683334 — intervention group
Group type: COMPARATOR
Intervention: Neostigmine 50 microg kg(‐1) with glycopyrrolate 10 microg kg(‐1)
Number of subjects: 98
Study 18454877 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor control exercises
Number of subjects: 172
Study 18454877 — intervention group
Group type: COMPARATOR
Intervention: Graded activity program
Number of subjects: 172
Study 16180595 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily stretch positioning for wrist and finger flexors and shoulder adductors and internal rotators, two 30-min stretches per day for up to 12 weeks post stroke.
Number of subjects: 25
Study 16180595 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 25
Study 12796526 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic therapy
Number of subjects: 59
Study 10234717 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrioventricular delay of 200 ms
Number of subjects: 15
Study 10234717 — intervention group
Group type: COMPARATOR
Intervention: Atrioventricular delay of 100 ms
Number of subjects: 15
Study 8609746 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 2 g single preoperative dose
Number of subjects: 2195
Study 8609746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2195
Study 1460707 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mm polytetrafluoroethylene (PTFE)
Number of subjects: 96
Study 1460707 — intervention group
Group type: COMPARATOR
Intervention: 6 mm human umbilical vein (HUV)
Number of subjects: 96
Study 6704274 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (0.5‐1.5%)
Number of subjects: 20
Study 6704274 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (mean 17 micrograms kg‐1)
Number of subjects: 20
Study 31682747 — intervention group
Group type: EXPERIMENTAL
Intervention: First Breath program (new version)
Number of subjects: 88
Study 30651946 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiology taping
Number of subjects: 19
Study 30651946 — intervention group
Group type: COMPARATOR
Intervention: Placebo taping
Number of subjects: 19
Study 25138195 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual Placement and Support (IPS)
Number of subjects: 109
Study 25138195 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 109
Study 25250613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitafloxacin 50 mg
Number of subjects: 12
Study 25250613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitafloxacin 100 mg
Number of subjects: 12
Study 25250613 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitafloxacin 200 mg
Number of subjects: 12
Study 22920446 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronically enabled discharge reconciliation and communication
Number of subjects: 3714
Study 22920446 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3714
Study 19935818 — intervention group
Group type: EXPERIMENTAL
Intervention: HIFV (nonrestrictive messages to increase fruit and vegetable intake)
Number of subjects: 68
Study 19935818 — intervention group
Group type: COMPARATOR
Intervention: LOFAT (restrictive messages to limit high-fat foods)
Number of subjects: 68
Study 17548731 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cooling with 4 degrees C normal saline (500 to 2000 mL)
Number of subjects: 125
Study 17548731 — intervention group
Group type: COMPARATOR
Intervention: Standard care without cooling
Number of subjects: 125
Study 17548731 — intervention group
Group type: EXPERIMENTAL
Intervention: In-field cooling
Number of subjects: 125
Study 17548731 — intervention group
Group type: EXPERIMENTAL
Intervention: In-field cooling in ventricular fibrillation patients
Number of subjects: 125
Study 15562142 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized tobramycin (300 mg twice daily for 6 months)
Number of subjects: 30
Study 15562142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11914208 — intervention group
Group type: EXPERIMENTAL
Intervention: PCIOL corneas stored in organ culture for 7 days
Number of subjects: 27
Study 11914208 — intervention group
Group type: COMPARATOR
Intervention: Phakic controls stored in organ culture for 7 days
Number of subjects: 27
Study 11914208 — intervention group
Group type: EXPERIMENTAL
Intervention: PCIOL corneas stored in organ culture for up to 2 weeks
Number of subjects: 27
Study 11914208 — intervention group
Group type: COMPARATOR
Intervention: Phakic controls stored in organ culture for up to 2 weeks
Number of subjects: 27
Study 9539304 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (DDAVP) 10 microg i.v.
Number of subjects: 17
Study 9539304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovine corticotropin-releasing hormone (oCRH) 1 microg/kg body weight
Number of subjects: 17
Study 9539304 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ACTH 5 microg i.v.
Number of subjects: 17
Study 9539304 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 7624918 — intervention group
Group type: EXPERIMENTAL
Intervention: New assay for measuring AChE activity
Number of subjects: 0
Study 1776334 — intervention group
Group type: EXPERIMENTAL
Intervention: molsidomine (4 mg)
Number of subjects: 12
Study 1776334 — intervention group
Group type: COMPARATOR
Intervention: isosorbide‐5‐mononitrate (ISMN, 20 mg)
Number of subjects: 12
Study 1776334 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 6295133 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial surgery with adequate exploration of the opposite kidney
Number of subjects: 18
Study 6295133 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephroblastomatosis histologically
Number of subjects: 18
Study 6295133 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicentric origin of tumors
Number of subjects: 18
Study 6295133 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival free of disease
Number of subjects: 18